ABSTRACT Forty-five consecutive patients with polymorphous ventricular tachycardia (PVT) were studied. The arrhythmia proved to be of a drug-related cause in 27 and due to an electrolyte disorder in four patients. Coexistent cardiac diseases without metabolic or drug-related abnormalities included ischemic heart disease in three, cardiomyopathy in three, and mitral valve prolapse in two. PVT was exercise-induced in four and associated with bradyarrhythmias in two. A prolonged QT or corrected QT interval was inconsistently related to the occurrence of PVT. In patients in whom PVT was induced by certain type I drugs, other type I antiarrhythmic drugs were usually either ineffective or resulted in aggravation of arrhythmia. For the group as a whole, treatment with lidocaine resulted in inconsistent beneficial effects, while cardiac pacing was almost universally effective for those with drug-induced PVT, regardless of the length of the QT interval. Long-term amiodarone therapy proved safe and effective for 12 of the 24 patients with drug-induced PVT who required long-term therapy for their original arrhythmia. We conclude that identification of PVT is the key clinical issue and that the QT interval is not necessarily the prime abnormality nor the variable to be considered in predicting success of therapy. Temporary cardiac pacing appears to be very effective in the short-term management of these patients. Use of type I antiarrhythmic agents in patients with drug-induced PVT generally resulted in aggravation of arrhythmia. In contrast, long-term amiodarone therapy for control of the original arrhythmia appears to be a promising approach for those with PVT associated with type I agents. tance of the QT interval in patients with this arrhythmia.
THE CLINICAL characterization of polymorphous ventricular tachycardia (PVT) has been incomplete. The definition of PVT we have used is similar to that proposed by the North American Society of Pacing and Electrophysiology, namely ventricular tachycardia with an unstable (continuously varying) QRS complex morphology in any recorded electrocardiographic lead.' In addition, we require a ventricular rate greater than 200/min for at least 10 complexes. This definition includes but is not limited to the classic torsade de pointes pattern.2 Diagnostic criteria for torsade de pointes includes the presence of a prolonged QT interval, and others have emphasized the clinical importance of this arrhythmia.S ince the clinical implication of PVT is not clear, the purpose of the present study is threefold: (1) to define the clinical characteristics of PVT, (2) to assess tance of the QT interval in patients with this arrhythmia.
Materials and methods
Data for this study were collected retrospectively for 1 year and prospectively over 1.8 years for all patients admitted to the University of California Medical Center, San Francisco, with the diagnosis of PVT. PVT was defined as a rapid (> 200/min) irregular ventricular tachycardia with continuous variation in QRS complexes of greater than 10 beat duration. This definition included but was not limited to the classic torsade de pointes pattern. All rhythm strips were reviewed to ascertain that the tachycardia fulfilled the above requirements. All patients had symptomatic arrhythmias and were continuously monitored in a coronary care unit. PVT was defined as drug induced if it developed as a new rhythm disturbance after initiation of drug therapy and it disappeared after cessation of administration of that drug. A total of 45 patients met these criteria and were included in the study. We excluded all patients who developed PVT as part of a preterminal cardiac state (i.e., those with severe end-stage heart failure or cardiogenic shock). In addition, patients with familial or idiopathic long QT syndrome were excluded, since these patients are described in detail in a separate report.8 Patients were included only if 12-lead sinus rhythm electrocardiograms had been recorded in them either just before or during interludes between bouts of PVT. Posttreatment QT intervals were not measured in seven patients who received permanent pacemakers.
The following data were extracted from the medical records: age, sex, cardiac diagnosis, concurrent drug therapy, and drug and electrolyte levels. The QT interval and the corrected QT to be absent at follow-up after hospital discharge. A treatment (QTc) were determined from a 12-lead sinus rhythm electrocarregiinen was deemed unsuccessful if PVT frequency remained diogram that was obtained on hospital admission, during interthe same or increased or if PVT recurred more than four drug ludes between episodes of active arrhythmia, and just before half-lives after discontinuing an offending drug. The total numdischarge. Retrospective data were obtained by examination of ber of episodes of PVT during short-term therapy was recorded all medical records, including daily electrocardiographic (see Alnitial therapy included discontinuation of the offending drug listed in table 1.
PVT. All patients with drug-induced PVT had associated organic heart disease. whether used singly (patients 7 and 25) or with phenytoin (patient 20). Therapy with class IA antiarrhythmic agents was initiated 18 to 48 hr after the last recorded episode of PVT in 12 patients. PVT either recurred or increased in frequency in 10. Two patients (Nos. 8 and 12) developed PVT in association with quinidine but responded to procainamide (one patient) and disopyramide (one patient). Both the QT and QTc for these two patients were clearly prolonged. One patient (No. 6) received a bolus infusion of intravenous amiodarone (5 mg/kg) followed by an infusion of 1 g over 24 hr, which resulted in PVT control. None of these patients received intravenous Mg + or isoproterenol.
Among the three patients who developed PVT while taking amiodarone, associated hypokalemia was found in one and bradyarrhythmias were found in two. The patients were treated with phenytoin (three patients), K' replacement (one patient), or long-term cardiac pacing (two patients).
Long-term antiarrhythmic treatment. Long-term antiarrhythmic therapy was discontinued in eight patients because the original indication for its use was marginal. Seven patients were treated with digitalis, verap- PVT only after initiation of diuretic therapy, which resulted in hypokalemia. Her QT and QTc were prolonged at the time of PVT, but these intervals returned to baseline values when her potassium levels were corrected and her thioridazine discontinued. Only one other patient in this category had a prolonged QT interval, and this interval remained prolonged even after Ca+ + repletion. In all four patients, PVT responded to correction of the abnormality.
Exercise-induced PVT Four patients had PVT that was associated with exercise: two had no organic heart disease, another had Ebstein's anomaly associated with mitral and tricuspid prolapse, and a third had arrhythmogenic right ventricular dysplasia. The control QT interval was normal for each patient, but became abnormally prolonged in one after therapy with ,3-blockers. All of these patients responded to /3-blockers alone or in combination with verapamil.
Acute myocardial infarction -cardiomyopathy. Three patients developed PVT after acute myocardial infarction (Nos. 36, 37, and 38) and all showed a variable spontaneous cycle length preceding initiation of PVT (figure 3). These patients were treated with nitrates, /-blockers, and type I drugs, but all required amiodarone for arrhythmia control. Two patients with bradycardiarelated PVT responded to penranent cardiac pacing and two patients with severe congestive heart failure and chronic lung disease responded to treatment of the underlying condition. One patient with cardiomyopathy had a history of recurrent syncope and documented cardiac arrest (PVT degenerating to ventricular fibrillation). Twenty four-hour Holter recordings showed recurrent episodes of PVT. She was treated with amiodarone and an automatic implantable cardioverter defibrillator (AICD) was implanted. Over a follow-up period of 12 months, she has been without syncope and without discharge of her AICD. Prior drug trials with type LA antiarrhythmic agents for patients in the miscellaneous cause category ( It has been emphasized that those with classic torsade de pointes tend to respond to maneuvers that shorten the QT (i.e., cardiac pacing or isoproterenol infusion). 3 5,6 In contrast, those with PVT and a normal QT are thought to respond to conventional type I antiarrhythmic drugs.3 In addition, one report suggests that those patients with drug-induced torsade de pointes show markedly prolonged QT intervals (> 0.6 sec).6 Our data suggest that the above formulation may not be relevant for the majority of patients presenting 346 with drug-induced PVT. We found that in the majority of patients with PVT the tachycardia was drug induced and that the QT interval was of limited value in deciding on proper therapy for these patients. For example, only three patients with drug-induced PVT showed QT prolongation of greater than 0.60 sec, suggesting that this criterion is not applicable in the diagnosis of druginduced PVT. In addition, six patients with drug-induced PVT and normal (or slightly prolonged) QT intervals failed to respond to other type I antiarrhythmic agents. Furthermore, temporary cardiac pacing proved effective regardless of whether the QT was normal or prolonged. Finally, two patients (Nos. 8 and 12) with clearly prolonged QT intervals who had quinidine-induced PVT responded to procainamide (one patient) and disopyramide (one patient). These data suggest that recognition of the PVT pattern as described (see Materials and methods) is crucial in arriving at proper therapy, while the absolute or corrected QT is of limited value.
Reports by Denes et al.`and Kay et al. 12 emphasize the consistent finding of a pause that precedes the onset of drug-induced torsade de pointes. Of interest was our finding that this same pattern was almost universally present in those with drug-induced PVT. This finding and the beneficial response to pacing may reflect a pathogenetic mechanism common to both torsade de pointes and PVT. Pause-related PVT was not a consistent finding in those with PVT unassociated with drugs. For example, in those with PVT associated with exercise, the arrhythmia became apparent only after a critical increase in sinus rate was achieved.
Time elapsed from onset of drug therapy to PVT. An important finding in our study relates to the onset of PVT. One-half of the patients with type I drug-induced PVT (12 of 24) developed the tachycardia within 4 days of initiation of drug therapy. In eight, PVT developed weeks to years after initiation of the offending drug. In those with late-onset PVT, associated hypokalemia was found in two, bradycardia was noted in one, and in another patient PVT was observed after successful cardiac surgery for tricuspid valve replacement. As a group, these patients developed PVT while taking their regular dosage of medication. Drug blood levels were available for 17 patients and were found to be in the subtherapeutic or therapeutic range in 15 of the 17, suggesting that drug-induced PVT was an idiosyncratic response. Thus, a 4 day hospital stay for all patients initiated on type I antiarrhythmic drug therapy should be sufficient to detect a significant number of patients at risk for development of PVT. Similar findings have been reported in a prospective evaluation of quinidine therapy. '6 Miscellaneous causes of PVT. Torsade de pointes associated with electrolyte disorders, myocardial ischemia, and bradyarrhythmias has been described in previous reports.' 7 21 Two of the four patients with electrolyte abnormalities (Nos. 30 and 31) exhibited a prolonged QT interval. In patient 30, the prolonged QT may have been due to the underlying cardiomyopathy since correction of the hypocalcemia (while associated with abatement of PVT) failed to normalize the QT interval. In the 10 patients with ischemic heart disease or bradyarrhythmia-related PVT, the QT was either normal or only slightly prolonged. Of particular interest are four patients with exercise-induced PVT. None of these patients had coronary artery disease but two had organic cardiac disease (Ebstein's anomaly in patient 33, and arrhythmogenic right ventricular dysplasia in patient 34). The QT interval in these patients was either normal or borderline prolonged and each responded (as judged by repeated exercise treadmill testing) to ,3-blockers alone or in combination with verapamil (patient 33). Exercise-induced "pleomorphic" ventricular tachycardia in the absence of coronary artery disease has been previously described.22,23 induced PVT fell into the range expected for those treated with type I agents but who never experienced PVT* (figure 4). For this reason, in our study, those patients with drug-induced PVT were not considered to have a clearly prolonged QT interval unless this interval exceeded 0.48 sec. Moreover, our data suggest that the QT interval cannot be used as a reliable guide for deciding on short-or long-term antiarrhythmic therapy in patients with PVT because (1) most patients with drug-induced PVT and a normal QT failed to respond to other type I drugs, (2) cardiac pacing was almost universally effective regardless of the QT interval, and (3) long-term therapy with amiodarone proved effective in patients with type I drug-induced PVT and this therapy was usually associated with further lengthening of the QT interval.
Clinical implications. The most important finding of our study was that PVT, whether associated with normal or slightly prolonged QT intervals, was usually drug induced. Drug-induced PVT was almost always preceded by sinus bradycardia or a pause, while this *Orinius E: Personal communication.
finding was much less consistent in those with PVT that was not drug related. We suspect that some of the patients with drug-induced PVT were treated with other type I agents, in part because either the QT interval was normal or the characteristic pattern of twisting of the QRS around an isoelectric line was not present. We therefore believe that the critical element in the proper management of these patients is recognition of the PVT pattern. Intravenous lidocaine was inconsistently effective. Intravenous bretylium was ineffective and probably proarrhythmic, while cardiac pacing was almost universally effective in arrhythmia control, regardless of the QT interval. A 4 day hospital stay would be expected to detect approximately half of patients susceptible to type I drug-induced PVT. In addition, other possible aggravating causes, such as occurrence of bradyarrhythmia, electrolyte disorders, use of diuretic agents, or cardiac surgery should be evaluated. Our preliminary findings suggest that amiodarone may prove to be a suitable therapeutic option for longterm control of the original arrhythmia in patients with drug-induced PVT.
